These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10603491)

  • 41. [Serotonin hypothesis and pulmonary artery hypertension].
    Kloza M; Baranowska-Kuczko M; Pędzińska-Betiuk A; Jackowski K; Kozłowska H
    Postepy Hig Med Dosw (Online); 2014 Jun; 68():738-48. PubMed ID: 24934532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The serotonin hypothesis of pulmonary hypertension revisited.
    Maclean MR; Dempsie Y
    Adv Exp Med Biol; 2010; 661():309-22. PubMed ID: 20204739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Serotonin syndrome as a result of concomitant use of paroxetine and sumatriptan].
    Hendrix Y; van Zagten MS
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):888-90. PubMed ID: 15868995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine.
    Mark EJ; Patalas ED; Chang HT; Evans RJ; Kessler SC
    N Engl J Med; 1997 Aug; 337(9):602-6. PubMed ID: 9271482
    [No Abstract]   [Full Text] [Related]  

  • 45. Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts.
    Tellier P
    Ann Med Interne (Paris); 2001 Nov; 152(7):429-36. PubMed ID: 11965083
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of systemic phenylpropanolamine and fenfluramine on serotonin activity within rat paraventricular hypothalamus.
    McMahon LR; Wellman PJ
    Physiol Behav; 1996 Jan; 59(1):63-9. PubMed ID: 8848492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
    Fitzgerald LW; Burn TC; Brown BS; Patterson JP; Corjay MH; Valentine PA; Sun JH; Link JR; Abbaszade I; Hollis JM; Largent BL; Hartig PR; Hollis GF; Meunier PC; Robichaud AJ; Robertson DW
    Mol Pharmacol; 2000 Jan; 57(1):75-81. PubMed ID: 10617681
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus.
    Delaney C; Gien J; Grover TR; Roe G; Abman SH
    Am J Physiol Lung Cell Mol Physiol; 2011 Dec; 301(6):L937-44. PubMed ID: 21908589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Appetite suppressants and pulmonary hypertension.
    Voelkel NF
    Thorax; 1997 Aug; 52 Suppl 3(Suppl 3):S63-7. PubMed ID: 9381430
    [No Abstract]   [Full Text] [Related]  

  • 50. The serotonergic appetite suppressant fenfluramine. Reappraisal and rejection.
    Curzon G; Gibson EL
    Adv Exp Med Biol; 1999; 467():95-100. PubMed ID: 10721044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935.
    Keegan A; Morecroft I; Smillie D; Hicks MN; MacLean MR
    Circ Res; 2001 Dec; 89(12):1231-9. PubMed ID: 11739290
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The acute effects of dexfenfluramine on human and porcine pulmonary vascular tone and resistance.
    Higenbottam T; Marriott H; Cremona G; Laude E; Bee D
    Chest; 1999 Oct; 116(4):921-30. PubMed ID: 10531154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of the Ongoing Story of Appetite Suppressants, Serotonin Pathway, and Pulmonary Vascular Disease.
    Bazan IS; Fares WH
    Am J Cardiol; 2016 May; 117(10):1691-1696. PubMed ID: 27018933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 5-Hydroxytryptamine and platelets: uptake and aggregation in hypoxic pulmonary hypertensive rats.
    Awabdy D; Bryan-Lluka LJ; Wanstall JC
    Eur J Pharmacol; 2003 Jan; 459(1):1-7. PubMed ID: 12505528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unusual hypotension and bradycardia in a patient receiving fenfluramine, phentermine, and fluoxetine.
    Rich JM; Njo L; Roberts KW; Smith KP
    Anesthesiology; 1998 Feb; 88(2):529-31. PubMed ID: 9477076
    [No Abstract]   [Full Text] [Related]  

  • 56. A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension.
    Weir EK; Reeve HL; Johnson G; Michelakis ED; Nelson DP; Archer SL
    Chest; 1998 Sep; 114(3 Suppl):200S-204S. PubMed ID: 9741569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the 5-HT system: Potential side effects.
    Hoyer D
    Neuropharmacology; 2020 Nov; 179():108233. PubMed ID: 32805212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High altitude may be synergistic with pulmonary hazards of appetite control medications fenfluramine and dexfenfluramine.
    Davis WM; Waters IW
    Med Hypotheses; 1997 Dec; 49(6):509-12. PubMed ID: 9466375
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension.
    Rothman RB; Ayestas MA; Dersch CM; Baumann MH
    Circulation; 1999 Aug; 100(8):869-75. PubMed ID: 10458725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Milnacipran, a serotonin and norepinephrine reuptake inhibitor, induces appetite-suppressing effects without inducing hypothalamic stress responses in mice.
    Nonogaki K; Nozue K; Kuboki T; Oka Y
    Am J Physiol Regul Integr Comp Physiol; 2007 May; 292(5):R1775-81. PubMed ID: 17218444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.